Ultrafine nanoparticles comprising a functionalized polyorganosiloxane matrix and including metal complexes; method for obtaining same and uses thereof in medical imaging and/or therapy
The invention relates to novel biocompatible hybrid nanoparticles of very small size, useful in particular for diagnostics and/or therapy. The purpose of the invention is to offer novel nanoparticles which are useful in particular as contrast agents in imaging (e.g. MRD and/or in other diagnostic techniques and/or as therapeutic agents, which give better performance than the known nanoparticles of the same type and which combine both a small size (for example less than 20 nm) and a high loading with metals (e.g. rare earths), in particular so as to have, in imaging (e.g. MRI), strong intensification and a correct response (increased relaxivity) at high frequencies. Thus, the nanoparticles according to the invention, with diameter d 1 between 1 and 20 nm, each comprise a polyorganosiloxane (POS) matrix including gadolinium cations optionally associated with doping cations; a chelating graft C 1 DTPABA (diethylenetriaminepentaacetic acid bisanhydride) bound to the POS matrix by an —Si—C— covalent bond, and present in sufficient quantity to be able to complex all the gadolinium cations; and optionally another functionalizing graft Gf* bound to the POS matrix by an —Si—C— covalent bond (where Gf* can be derived from a hydrophilic compound (PEG); from a compound having an active ingredient PA1; from a targeting compound; from a luminescent compound (fluorescein). The method for the production of these nanoparticles and the applications thereof in imaging and in therapy also form part of the invention.
1 . A method for targeting a radiosensitizing agent to a tumor in a subject in need thereof, said method comprising:
administering a suspension of nanoparticles as radiosensitizing agents, to said subject in need thereof, wherein each of said nanoparticles comprises:
a polyorganosiloxane matrix,
an efficient amount of a chelating functionalizing graft bound to the polyorganosiloxane matrix by an —Si—C— covalent bond, wherein said chelating functionalizing graft is obtained by functionalizing the polyorganosiloxane matrix with DOTAGA anhydride of the following formula:
and
an efficient amount of metallic cation M n+ complexed to said chelating functionalizing graft, wherein M n+ is Gd 3+ ,
and wherein said nanoparticles have a diameter comprised between 1 and 8 nm, said nanoparticles have a molecular weight, expressed in kDa, greater than or equal to 2 and less than or equal to 200, and said nanoparticles do not comprise a crystallized core of metal oxide.
2 . The method of claim 1 , wherein an atom % ratio (M/Si) is from 10 to 60.
3 . The method of claim 1 , wherein said chelating graft is in excess relative to said cations Gd 3+ .
4 . The method of claim 1 , wherein a relaxivity r 1 per Gd 3+ ion is greater than 5 mM −1 (of Gd 3+ ion).s −1 for a frequency of 20 Mhz and/or a relaxivity r 1 per Gd 3+ ion at 60 MHz is greater than relaxivity r 1 per Gd 3+ ion at 20 MHz.
5 . A method for treating a tumor in a subject in need thereof, said method comprising administering an efficient amount of nanoparticles in combination with radiotherapy to said subject, wherein each of said nanoparticles comprises:
a polyorganosiloxane matrix,
an efficient amount of a chelating functionalizing graft bound to the polyorganosiloxane matrix by an —Si—C— covalent bond, wherein said chelating functionalizing graft is obtained by functionalizing the polyorganosiloxane matrix with DOTAGA anhydride of the following formula:
and
an efficient amount of metallic cation M n+ complexed to said chelating functionalizing graft, wherein M n+ is Gd 3+ , M is selected from the subgroups comprising:
and wherein said nanoparticles have a diameter comprised between 1 and 8 nm, said nanoparticles have a molecular weight, expressed in kDa, greater than or equal to 2 and less than or equal to 200, and said nanoparticles do not comprise a crystallized core of metal oxide.
6 . The method of claim 5 , wherein an atom % ratio (M/Si) is from 10 to 60.
7 . The method of claim 5 , wherein said chelating graft is in excess relative to said cations Gd 3+ .
8 . The method of claim 5 , wherein a relaxivity r 1 per Gd 3+ ion is greater than 5 mM −1 (of Gd 3+ ion).s −1 for a frequency of 20 Mhz and/or a relaxivity r 1 per Gd 3+ ion at 60 MHz is greater than relaxivity r 1 per Gd 3+ ion at 20 MHz.